Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.74 |
| ▸ | ESRRG | P62508 | 11/20 | 0.71 |
| ▸ | ESRRB | O95718 | 6/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | PGR | P06401 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | PLD2 | O14939 | 1/20 | 0.71 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.71 |
| ▸ | ESRRA | P11474 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409444 | 1.00 | ESR1 (0.74) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL10829107 | 0.85 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL10048291 | 0.85 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL20224018 | 0.84 | ESR1 (0.78) | ESR1ESRRGESRRBESR2MAPT | |
| Afimoxifene SCHEMBL9189 | 0.83 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| Afimoxifene SCHEMBL2132301 | 0.83 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| Afimoxifene SCHEMBL640496 | 0.83 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL2165503 | 0.83 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL15668666 | 0.83 | ESR1 (1.00) | ESR1ESRRGESRRBESR2MAPT | |
| SCHEMBL4675620 | 0.83 | ESR1 (0.56) | ESR1ESRRGESRRBESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397382-A4 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2005-08-24 | — | — | EP | claimed |
| EP-1397382-A2 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2004-03-17 | — | — | EP | claimed |
| US-20030143559-A1 | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions | NOVARTIS AG (CH) | 2003-07-31 | — | — | US | claimed |
| WO-2002097050-A2 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2002-12-05 | — | — | WO | claimed |
| EP-2060582-A1 | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions | Novartis Ag (CH) | 2009-05-20 | — | — | EP | disclosed |
| EP-1397382-B1 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7381813-B2 | Nucleic acids encoding estrogen receptor ligand binding domain variants | NOVARTIS AG (CH) | 2008-06-03 | — | — | US | disclosed |
| EP-1397382-A4 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| EP-1397382-A2 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-20030143559-A1 | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions | NOVARTIS AG (CH) | 2003-07-31 | — | — | US | disclosed |
| WO-2002097050-A2 | NOVEL ESTROGEN RECEPTOR LIGAND BINDING DOMAIN VARIANTS AND NOVEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143559-A1 | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions | ESRRB, ESRRG, ESRRA | ESR1 5/4885ESRRG 2/4885ESRRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.